Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well …
Full BDTX analysis →
Competitive advantage assessment
Key strengths
Cash Generation ConsistentCash generation is consistent (score 0.96), indicating reliable business model.
ROIC Sustainably Above PeersROIC at 85.8th percentile exceeds peers and WACC, demonstrating superior capital allocation.
Key risks
Commodity Pressure / Weak DifferentiationGross margin at 0th percentile with high volatility suggests weak pricing power or commoditized products.
Revenue Volatility Signals Weak StickinessRevenue volatility is high (stability score 0.00), suggesting weak customer stickiness.
The dashed ring is the peer median. Defense scores are percentile ranks
against peers, so 50 is roughly the typical company in this group.
Upgrade to unlock the signals and evidence behind each defense.
Premium access
Unlock full defense analysis
Get key signals, strengths, and risks for every moat dimension.
Black Diamond Therapeutics, Inc ranks #2 of 713
scored companies in Biotechnology by moat score — the top 1%.
The widest moat in the group is Royalty Pharma plc (RPRX)
at 85/100.
Moat scores for companies ranked near BDTX in Biotechnology
Pricing power is the ability to raise prices without losing volume.
Cost Advantage
Score 92
· 15% of the moat score
A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.
Customer Stickiness
Score 96
· 15% of the moat score
Stickiness is what makes revenue repeat without being re-won every year.
Capital Efficiency
Score 79
· 18% of the moat score
Capital efficiency asks what the company earns on the money tied up in the business.
Resilience
Score 69
· 17% of the moat score
Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.
Scale & Market Position
Score 91
· 15% of the moat score
Scale matters only when it converts into economics.
What is Black Diamond Therapeutics, Inc's moat score?
Black Diamond Therapeutics, Inc (BDTX) scores 84 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as strong. It ranks #2 of 713 scored companies in Biotechnology, the top 1%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Customer Stickiness (96/100) and its weakest is Resilience (69/100).
How does Black Diamond Therapeutics, Inc compare with other Biotechnology companies?
Black Diamond Therapeutics, Inc ranks #2 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are Royalty Pharma plc (RPRX) at 85 just above it and United Therapeutics Corporation (UTHR) at 84 just below it.
How is the moat score calculated?
Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.
Why is Black Diamond Therapeutics, Inc scored with the Corporate Default template?
Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.
Which competitive defenses are measured for Black Diamond Therapeutics, Inc?
The Corporate Default template measures 6 defenses, and BDTX scores: Pricing Power (91), Cost Advantage (92), Customer Stickiness (96), Capital Efficiency (79), Resilience (69), Scale & Market Position (91). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.
We value your privacy
We use cookies to enhance your browsing experience, analyze site traffic, and personalize content. By clicking 'Accept All', you consent to our use of cookies.
Read our cookie policy
Cookie Preferences
Manage your cookie preferences. Essential cookies are always enabled.